Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDEA-070 is a topical formulation of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen, utilizing IDEA AG's proprietary Transfersome delivery technology. Transfersomes are highly deformable lipid vesicles designed to bypass the skin's stratum corneum barrier, allowing for deeper penetration of the active ingredient into the dermis and underlying tissues. IDEA-070 was specifically developed to manage the acute pain and inflammation that occurs during and after photodynamic therapy (PDT) for actinic keratosis. By inhibiting cyclooxygenase enzymes (COX-1 and COX-2), ketoprofen reduces the production of pro-inflammatory prostaglandins at the site of treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IDEA-070.